Larvol Delta - Results-from-Cognition-Therapeutics-Phase-2-SHINE-Study-of-CT1812-in-MildtoModerate-Alzheimers-Disease-Accepted-for-Presentation-at-AAIC

Elayta (CT1812) - Cognition Therap

https://www.globenewswire.com/news-release/2024/07/02/2907325/0/en/Results-from-Cognition-Therapeutics-Phase-2-SHINE-Study-of-CT1812-in-Mild-to-Moderate-Alzheimer-s-Disease-Accepted-for-Presentation-at-AAIC.html

Jul 2, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next